NASDAQ:PODD - Insulet Stock Price, News & Analysis

$143.24
-1.28 (-0.89 %)
(As of 09/15/2019 04:00 PM ET)
Today's Range
$141.0730
Now: $143.24
$144.14
50-Day Range
$118.45
MA: $144.89
$158.57
52-Week Range
$70.80
Now: $143.24
$168.00
Volume954,716 shs
Average Volume1.12 million shs
Market Capitalization$8.63 billion
P/E Ratio2,864.80
Dividend YieldN/A
Beta1.01
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$563.82 million
Cash Flow$0.3177 per share
Book Value$3.59 per share

Profitability

Net Income$3.29 million

Miscellaneous

Employees1,169
Market Cap$8.63 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.


Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings data on Monday, August, 5th. The medical instruments supplier reported $0.02 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.01. The medical instruments supplier earned $177.10 million during the quarter, compared to the consensus estimate of $163.63 million. Insulet had a net margin of 2.66% and a return on equity of 7.85%. Insulet's revenue for the quarter was up 42.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.03) EPS. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Insulet.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its third quarter 2019 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $174-181 million, compared to the consensus revenue estimate of $172.7 million.

What price target have analysts set for PODD?

14 analysts have issued 1 year price objectives for Insulet's shares. Their forecasts range from $100.00 to $160.00. On average, they anticipate Insulet's stock price to reach $132.6923 in the next year. This suggests that the stock has a possible downside of 7.4%. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

Has Insulet been receiving favorable news coverage?

News headlines about PODD stock have been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insulet earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Insulet.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), Tandem Diabetes Care (TNDM), Splunk (SPLK), Alibaba Group (BABA), Netflix (NFLX), ServiceNow (NOW), EXACT Sciences (EXAS), Coupa Software (COUP), Veeva Systems (VEEV) and BioTelemetry (BEAT).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

Who are Insulet's major shareholders?

Insulet's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.77%), Primecap Management Co. CA (7.56%), William Blair Investment Management LLC (3.87%), JPMorgan Chase & Co. (2.71%), Waddell & Reed Financial Inc. (1.39%) and Marshall Wace North America L.P. (1.22%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Primecap Management Co. CA, Point72 Asset Management L.P., UBS Asset Management Americas Inc., KAMES CAPITAL plc, Balyasny Asset Management LLC, Russell Investments Group Ltd. and Rockefeller Capital Management L.P.. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which institutional investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Nuveen Asset Management LLC, Rock Springs Capital Management LP, William Blair Investment Management LLC, Kornitzer Capital Management Inc. KS, Renaissance Technologies LLC, C WorldWide Group Holding A S and Jennison Associates LLC. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $143.24.

How big of a company is Insulet?

Insulet has a market capitalization of $8.63 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com/.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  574 (Vote Outperform)
Underperform Votes:  501 (Vote Underperform)
Total Votes:  1,075
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel